Prognostic Impact of Checkpoint Inhibitor Pneumonitis: Results from a Multicenter Prospective Observational Study (CS-Lung004)
Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening adverse event caused by anti-programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies. However, paradoxical findings have been reported regarding the association between overall survival (OS) and CIP. This study aimed to prospectively evaluate the relationship between the 2-year OS and CIP in patients receiving first-line treatment, including anti-PD-1/PD-L1 antibody therapy, using 3-month and 1-year landmark analyses. METHODS: A multicenter prospective observational study was conducted between December 2021 and November 2023 to evaluate the prognostic impact of CIP, based on timing and severity, in patients with non-small cell lung cancer (NSCLC). RESULTS: Although no significant difference in OS was observed between patients with and without CIP developed within 2 years or 1 year, the 3-month landmark analysis showed that patients who developed CIP within 3 months had significantly shorter OS than those who did not (median OS from the 3-months landmark: 11.1 months with CIP versus not reached without CIP; log-rank p = 0.011). In multivariate Cox regression analyses, using patients without CIP as the reference group, CIP within 3 months was significantly associated with impaired overall survival (any-grade CIP: hazard ratio [HR] = 2.22, 95% confidence interval [CI]=1.21-4.09; Grade 3-5 CIP: HR=3.37, 95% CI=1.57-7.23). CONCLUSION: This was the first prospective study to demonstrate the prognostic value of CIP. CIP within 3 months after the initiation of first-line treatment, including anti-PD-1/PD-L1 antibody, especially Grade 3-5 CIP, was associated with shorter OS in patients with NSCLC.
Source: Lung
Authors: Kakuhiro Yamaguchi, Jun Yano, Nobuhiro Kanaji, Tetsu Hirakawa, Naoko Matsumoto, Kozue Miyazaki, Tamio Okimoto, Chihiro Ando, Hisao Higo, Masaaki Yanai, Koji Kurose, Yasunari Nagasaki, Masako Watanabe, Kosuke Oyama, Yuko Toyoda, Yoshihiro Taguchi, Shimpei Tada, Suguru Fujita, Hiroshi Iwamoto, Noboru Hattori
Institutions: Hiroshima University Hospital, Hiroshima City Hiroshima Citizens Hospital, Kagawa University, Hiroshima University, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Higashihiroshima Medical Center, National Hospital Organization, Shimane University, Okayama Red Cross General Hospital, Okayama University Hospital, Tottori University Hospital, Kawasaki Medical School, Hiroshima City Asa Citizens Hospital, Kōchi University, Japanese Red Cross Kochi Hospital, Ehime University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,290
OpenAlex ID: W7236569364
